Nitazines in the UK: The Synthetic Opioid Challenge, Harm Reduction and Policy

In this Naked Scientists episode, the rise of nitazines, potent synthetic opioids, in the UK drugs market is explored alongside harm reduction strategies and policy debates.

• Nitazines are highly potent synthetic opioids that can cause life-threatening respiratory depression.
• Wedinos, a drug checking service, helps identify substances and reduce harm by informing users about what they are taking.
• Harm reduction measures such as naloxone distribution and supervised consumption rooms aim to lower overdose deaths.
• Policy discussions consider criminalization versus treatment, with experts arguing for evidence based approaches including safe heroin prescribing.

Overview and Context

The podcast examines nitazines, a class of high potency synthetic opioids, and their emergence in the United Kingdom. Scotland is highlighted as having the highest rate of drug related deaths in Europe, with England, Wales and Northern Ireland showing a roughly 60 percent rise over the last decade. Public health officials express concern about the availability of ultra potent synthetic opioids and their potentially devastating impact on vulnerable populations.

What Are Nitazines

Nitazines are a group of potent synthetic opioids originally developed as analgesics in the 1950s but never marketed due to safety concerns. In illicit supply they act as high potency substitutes for heroin, with risks including extremely shallow breathing and respiratory depression. Their potency means only tiny quantities are needed to achieve effects, increasing the potential for fatal overdoses among users who may not know what they are consuming.

UK Context and Evidence

The episode features perspectives from Peter Furlong of Change Grow Live and Rick Lynes of Public Health Wales and Wedinos, the UKs largest public drug testing service. Wedinos notes that nitazines have appeared in the illicit market since 2021 and have increasingly been detected in samples submitted as oxycodone or counterfeit benzodiazepines. Wedinos operates on a voluntary basis, so the service tests only what is submitted, representing a fraction of actual prevalence. The first nitazine sample was received in April 2021, and nitazine submissions have grown even if the overall prevalence is uncertain. The program explains that while nitazines constitute a small percentage of submissions, their increasing presence highlights a wider trend toward potent synthetic opioids in the drug supply.

Harm Reduction and Drug Checking

The podcast covers harm reduction strategies as a pragmatic approach to reduce harm for people who use drugs. Drug checking services, naloxone distribution, and safe consumption spaces are discussed as interventions that can identify dangerous substances, educate users about risks, and provide immediate medical support in overdose situations. Loop, a Cambridge based harm reduction group, emphasizes that drug checking offers information, risk assessment, and non judgemental support. The process typically involves submitting a sample to a local lab where identification and concentration analysis are performed within a 20 to 60 minute window. This rapid turnaround is crucial to prevent or mitigate harm from substances that have already been acquired and may be consumed soon after analysis.

Policy, Enforcement and Expert Opinion

The program features interviews with Adam Holland of the University of Bristol, who questions whether blanket criminalisation will deter nitazine use and suggests that a more nuanced policy approach may be needed. David Nutt, chair of Drug Science, argues for continued control of extremely potent opioids, while noting that the current framework—classifying nitazines as Class A—might not be sufficient to deter possession given the strong social and health harms involved. He also advocates for improved toxicology testing in coroners offices to ensure better death data and faster public health responses. The episode discusses that the Psychoactive Substances Act previously criminalised production and supply but not possession, thereby complicating deterrence. The Home Office response highlights ongoing efforts to keep synthetic opioids off the streets, with a stance that overall UK quantities remain lower than other countries but that vigilance remains necessary.

Harm Reduction in Practice and Future Directions

Beyond drug checking and naloxone, there are calls for the opening of the UKs first drug consumption room in Glasgow, as well as broader considerations for safer clubs and festivals, and improved access to naloxone. The discussion also covers the potential for more lab made drugs to appear on the market as production shifts in response to policy and supply dynamics. The experts emphasize the need for better surveillance, testing, and treatment infrastructures that can support individuals through opioid dependence, including evidence based treatment models such as methadone or buprenorphine, and even heroin prescription programs in certain contexts. Overall, the podcast advocates a pragmatic, health-led approach to reducing deaths and harm rather than relying solely on punitive measures.

Key Takeaways

1. Nitazines pose a significant overdose risk due to their high potency and unpredictable composition. 2. Public health responses emphasize harm reduction, rapid drug checking, and timely overdose reversal with naloxone. 3. Policy discussions question the efficacy of criminalisation and argue for a more integrated approach that includes treatment and safe supply. 4. Improved coronial toxicology and surveillance are essential for timely public health action.